End-to-End Publication Management of BHI’s Manuscript in Frontiers in Medicine

Elizabeth Mehling, Co-Founder - Blue Horizon International 

Blue Horizon International (BHI) is a global leader in stem cell therapy, operating clinics worldwide. Their innovative treatments advance regenerative medicine, and they’ve built a reputation for delivering cutting-edge healthcare solutions. Academic publications were needed to back up BHI's expansion and to support regulatory and funding applications.

The Challenge

BHI had extensive clinical data from their global operations but needed expert writers to develop this raw data into a polished manuscript for a peer-reviewed journal. They also needed support managing the entire publication process, ensuring the data could be leveraged for regulatory approvals, including their Investigational New Drug (IND) application with the FDA and future grant applications.

The Solution

Co-Labb provided BHI with a full publication management service:

1. Initial Consultation and Data Organisation: We worked with BHI to understand their objectives and organize their patient data, ensuring the most impactful information paper could be developed based on the available data.
   

2. Manuscript Drafting: We developed a comprehensive manuscript inline with the scope of the target journal.
   

3. Revisions and Quality Control: The manuscript underwent several rounds of quality checks to meet journal guidelines, incorporating BHI’s feedback along the way.
   

4. Journal Submission and Peer Review Management: We formatted and submitted the manuscript to Frontiers in Medicine and managed all communication and revisions throughout the peer review process.

   
   

The Results

Co-Labb successfully published BHI’s clinical data in Frontiers in Medicine, a critical milestone supporting their IND application and future grant efforts. 

Ranked as a Q1 journal by both JIF and CiteScore, Frontiers in Medicine is amongst the highest ranked journals in its category (medicine).

Frontiers is the 3rd most-cited and 6th largest research publisher, with Frontiers in Medicine being one of the publishers most highly cited and impactful journals, with 54.7 million total views and downloads in 2023. Due to the viewership, this journal was chosen for maximum reach amongst the medical community.

To date, the article has received 1570 total views and downloads, an excellent result for a case series in a niche topic.

This publication has been a cornerstone of their ongoing regulatory submissions and funding, by providing peer-reviewed evidence for the safety and efficacy of their novel immunotherapy.

Elizabeth Mehling, Co-Founder - Blue Horizon International

Message from the Co-Labb Co-Founder

 “It’s been a pleasure working with Blue Horizon International on their publication journey. Helping them bring their novel immunotherapy to the forefront through a peer-reviewed journal publication is a testament to what can be achieved with a collaborative approach. We look forward to continuing our partnership as they move forward with their regulatory and scientific goals.”

Dr. Dan Sheridan, Co-founder of Co-Labb